SURGERY PARTNERS DL -,01

Surgery Partners has filed binding contractual documents to sell its stakes in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health. The two facilities are valued at about $1.15 billion, with Surgery Partners receiving roughly $795 million. The company simultaneously confirmed its 2026 guidance (revenue $3.35–3.45 billion; adjusted EBITDA at least $530 million, each excluding the transaction) and emphasized that the proceeds will be used to focus on outpatient surgery centers. The announcement pushed the stock markedly higher intraday; Q2 results are expected on August 10. » More on de.investing.com

Surgery Partners agreed to sell Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for about $1.15 billion, after which the stock rose roughly 5.8%. The company expects to receive approximately $795 million in consideration for its ownership interests and a substantial cash inflow at closing, subject to customary purchase price adjustments. The deal still requires various approvals, including physician consents and expiration of Hart‑Scott‑Rodino waiting periods; the partnership with Intermountain Health will remain in place and the physician ownership stake at Mountain View Hospital will be unchanged. Surgery Partners calls the transaction the largest step in its portfolio-optimization strategy, affirms its prior 2026 guidance (revenue $3.35–3.45 billion, adjusted EBITDA at least $530 million) and says it will disclose further details on the financial impact after closing. » More on de.investing.com

Surgery Partners closed at $11.53, a 52-week low, after a 45.77% decline over the past six months and a 51.11% drop over 12 months. InvestingPro classifies the stock as volatile (beta 1.94) but considers it undervalued at the current level, citing price targets between $14 and $25. UBS affirmed a buy rating with a $21 target, while RBC cut its target to $20 but kept an outperform rating. Activist Ortelius Advisors is calling for a leadership change; investors are watching the company’s response amid weaker 2026 forecasts and unresolved M&A expectations. » More on de.investing.com

Surgery Partners’ stock closed at $12.22, marking a 52-week low after losing about 49.38% over the past year. Despite the weakness, InvestingPro rates the stock as undervalued and analyst consensus shows an average upside of roughly 62%; a return to profitability is expected this year. TD Cowen and RBC cut their price targets to $20, while UBS maintained a “Buy” rating with a $21 target. Activist moves by Ortelius Advisors and the appointment of Lloyd Dean to the board point to a strategic realignment. » More on de.investing.com

Surgery Partners named Lloyd Dean as an independent member of the board of directors. Dean previously served as CEO of CommonSpirit Health and Dignity Health and brings extensive experience in health organizations, policy advising and governance roles. The release notes the current share price is near the 52‑week low and refers to an InvestingPro analysis that gives a fair value of $14.11. » More on de.investing.com